Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

NEUROCUPLE™ som ett opioidalternativ efter total knäledsplastik

10 november 2026 uppdaterad av: Jacques E. Chelly

NEUROCUPLE™s roll som ett alternativ till opioider efter total knäledsplastik hos patienter

The goal of this clinical trial is to learn if the NEUROCUPLE device can reduce pain and opioid use after primary unilateral total knee arthroplasty (TKA) in adults.

The main questions it aims to answer are:

  • Does the NEUROCUPLE device reduce postoperative pain at rest during the first 24 hours after TKA?
  • Does the NEUROCUPLE device reduce opioid consumption during the first 24 hours after TKA?

Researchers will compare the NEUROCUPLE device to a placebo device (identical in appearance but inactive) to see if the device reduces pain and opioid use after surgery.

Participants will:

  • Apply the NEUROCUPLE device or placebo device for 7 days following surgery
  • Have their pain and opioid use monitored through clinical records and patient reporting
  • Report pain at rest and during movement on postoperative Days 2 and 7
  • Be assessed for nausea, vomiting, device-related side effects, length of hospital stay, and overall satisfaction

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

274

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

  • Namn: Heather Margonari, DNP, FNP, BC
  • Telefonnummer: 412-623-1914
  • E-post: margonarih@upmc.edu

Studieorter

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Förenta staterna, 15232
        • UPMC Shadyside Hospital
        • Huvudutredare:
          • Jacques E. Chelly, MD, PhD, MBA
        • Kontakt:
        • Kontakt:
      • Pittsburgh, Pennsylvania, Förenta staterna, 15237
        • UPMC Passavant Hospital
        • Huvudutredare:
          • Jacques E. Chelly, MD, PhD, MBA
      • Pittsburgh, Pennsylvania, Förenta staterna, 15146
        • UPMC East Hospital
        • Huvudutredare:
          • Jacques E. Chelly, MD, PhD, MBA

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • >18 years of age
  • Scheduled for elective primary unilateral TKA

Exclusion Criteria:

  • Children (<18 yr.)
  • Pregnant women
  • Active alcoholism (defined as daily use of more than 1 liter of wine and /or 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)
  • Severe chronic pain condition that requires daily preoperative opioid dependence
  • Other concomitant surgery being performed in addition to TKA
  • Patients undergoing bilateral TKA
  • Patients undergoing knee replacement revision
  • Patients with limited mobility (in a wheelchair or requiring a walker)
  • Patients who are not returning home after surgery

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: NEUROCUPLE™ Group

This arm of subjects will receive the active NEUROCUPLE™ patch to wear for 7 days following their TKA surgery.

nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year. The patch will be worn for 7-days

Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications

Sham Comparator: Sham Group

This arm of subjects will receive the placebo (non-active, sham) patch to wear for 7 days following their TKA surgery.

Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications

Non-active placebo patch visually identical to NEUROCUPLE™ worn for 7 days following total knee arthroplasty.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Opioid Consumption
Tidsram: 0- 24 hours post-surgery

Total opioid consumption, expressed in milligrams of morphine equivalents (MME), during the first 24 hours following surgery.

Opioid use will be calculated using all available data sources, including in-hospital medication administration records and, when applicable, the state Prescription Drug Monitoring Program (PDMP).

MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, while higher MME values suggest increased opioid use and potentially greater pain or slower recovery.

0- 24 hours post-surgery
Pain at Rest Using Numerical Rating Scale (NRS)
Tidsram: 0-24 hours post-surgery

Pain at rest during the first 24 hours after surgery will be assessed using a Numerical Rating Scale (NRS; 0 = no pain, 10 = worst pain) and compared between the NEUROCUPLE™ patch group and the placebo patch group. Higher scores indicate worse pain

0-24 hours post-surgery

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pain Scores Using Numerical Rating Scale (NRS) at Rest and during Movement
Tidsram: Post-operative at Day 2 and Day 7

Pain will be assessed using a Numerical Rating Scale (0 = no pain, 10 = worst pain) at rest and during movement on postoperative Days 2 and 7. Higher scores indicate worse pain.

Post-operative at Day 2 and Day 7
Patient Satisfaction
Tidsram: at Post-operative Day 7

Patient satisfaction with recovery and device use will be assessed on postoperative Day 7 using standardized questionnaires. Scores range from 0 to 10, where 0 indicates the lowest level of satisfaction and 10 indicates the highest.

at Post-operative Day 7
Opioid Consumption
Tidsram: Post-Operative Day 0- Day 7

Total opioid consumption, expressed in milligrams of morphine equivalents (MME), will be recorded over the 7-day postoperative period.

Opioid use will be calculated using all available data sources, including in-hospital medication administration records and the state Prescription Drug Monitoring Program (PDMP) when applicable.

MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, whereas higher MME values suggest increased opioid use and potentially greater pain or slower recovery.

Post-Operative Day 0- Day 7
Postoperative Adverse Events and Device-Related Side Effects
Tidsram: Postoperative Days 0-7

The incidence of postoperative adverse events, including any events determined to be related to the study device, will be recorded and compared between the treatment groups during the 7-day postoperative period.

Lower incidence rates indicate fewer complications and a more favorable safety profile, whereas higher incidence rates suggest increased complications, potential device-related issues, or a less favorable safety profile.

Postoperative Days 0-7
Incidence of postoperative nausea and/or vomiting (yes/no)
Tidsram: Postoperative Days 0-7

Incidence and severity of postoperative nausea and vomiting will be recorded over the 7-day postoperative period as (yes/no) and compared between groups.

Postoperative Days 0-7
Postoperative Length of Stay
Tidsram: From the date of surgery until hospital discharge (within the 7-day study period)

Length of hospital stay, defined as the number of days from the date of surgery to the date of hospital discharge, will be recorded and compared between groups.

Lower length of stay values indicate faster recovery, fewer complications, and earlier readiness for discharge. Higher length of stay values suggest slower recovery, increased complications, or higher postoperative symptom burden.

From the date of surgery until hospital discharge (within the 7-day study period)

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Utredare

  • Huvudutredare: Jacques E. Chelly, MD, PhD, MBA, University of Pittsburgh / UPMC
  • Studierektor: Alisha Maslanka, BS, CCRC, University of Pittsburgh / UPMC
  • Studierektor: Heather Margonari,, University of Pittsburgh / UPMC

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 december 2026

Primärt slutförande (Beräknad)

1 augusti 2027

Avslutad studie (Beräknad)

1 november 2027

Studieregistreringsdatum

Först inskickad

23 februari 2026

Först inskickad som uppfyllde QC-kriterierna

23 februari 2026

Första postat (Faktisk)

27 februari 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera